American Council on Science and Health13d
The FDA Finally Removes a Huge Barrier to an Effective Schizophrenia Medicine
For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...
MedPage Today26d
FDA Eliminates Barrier to Clozapine, Plans to End REMS Program
As part of the overhaul, prescribers will no longer be required to report the results of absolute neutrophil count (ANC) blood tests before pharmacies dispense clozapine to patients. However ...
Monthly Prescribing Reference25d
FDA Eliminates Clozapine REMS Program Requirement
Prior to pharmacies dispensing clozapine, the FDA required patients to obtain and report a baseline absolute neutrophil count (ANC) blood test. In order to continue treatment, the ANC was to be ...
Medscape20d
FDA Ended Clozapine REMS. But Will It Increase Prescribing?
The ANC testing is part of labeling, as the drug poses a risk for neutropenia. The REMS required that physicians and pharmacists be certified to prescribe and dispense the drug, which was ...
AllAfrica on MSN6d
Liberia: Patient in Critical Condition Blames Elwa Hospital
Jamesetta J. Kugmeh, accuses doctors and nurses at ELWA Hospital in Paynesville of alleged operational blunder during ...
AllAfrica on MSN5d
ELWA Hospital Empathizes With Patient
The Management of ELWA Hospital in Paynesville has expressed deep empathy and extended prayers to Madam Jamesetta J. Kugmeh and her family regarding her deteriorating health condition after undergoing ...
Neurology Advisor17d
FDA Makes Access to Clozapine Easier for Patients With Schizophrenia
The FDA has eliminated the need for pharmacists to verify a patient's white blood cell count before dispensing the antipsychotic medication clozapine.
Targeted Oncology9d
Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...
Medindia16d
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg INDIANAPOLIS /PRNewswire/ -- Late-breaking results from Eli ...